Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.
About CLS-1: Treatment of obesity via modulation of chemical signaling relating to gut microbiota
Under the recently-announced microbiota modulation platform operated by Aptorum Group’s wholly-owned subsidiary Claves Life Sciences Limited, we have commenced the preclinical development of macromolecule candidate CLS-1 targeting the treatment of obesity. CLS-1 is undergoing lead optimization and is expected to progress into the IND enabling stage in 2020.
The prevalence of obesity continues to escalate globally; however, there is no current optimal therapy for this condition1. For the majority of obese patients, conventional medical therapies (i.e., diet, exercise, behavioral counseling) often have a high failure rate for the long term2. We believe current pharmacotherapy has limited efficacy and is associated with substantial safety issues, and this will provide immeasurable market opportunity for CLS-1.
Chemical signaling of gut microbiota is known to be one of the major causes of obesity1. CLS-1 is an orally administered non-absorbable macromolecule that modulates the metabolite excreted by gut microbiota with high affinity and specificity. In this way, we believe the absorption of this particular metabolite, which is linked to obesity, can be inhibited.
Aptorum Group is also pursuing two further indications based on the modulation of microbiota based chemical signaling involving the above large molecule technology, which we believe to be highly scalable and we hope to be making further announcements regarding our efforts in due course.
About SACT-1: Repurposed Drug Candidates for the Treatment of Neuroblastoma
Under the recently announced Smart-ACTTM computational drug discovery platform operated by our wholly-owned subsidiary Smart Pharma Group, Aptorum Group has completed computational screening of approximately 1,615 marketed drugs against 3 therapeutic target proteins to potentially tackle poor prognosis of neuroblastoma, i.e., a rare type of children’s cancer that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, especially in children3. For the high-risk group, the 5-year survival rate of this condition is around 40-50% as observed by the American Cancer Society.4 Aptorum Group has identified an array of repurposed candidates and has proceeded to evaluate them in cell-based and animal models in order to validate the candidates’ usage for such new indication and potential efficacies.
Aptorum Group is also pursuing two further indications under the Smart-ACTTM drug discovery platform and hopes to be making further announcements regarding our research in due course.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics subsidiary of Aptorum Group Limited. Claves focuses on the clinical development of therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the modulation of gut microbiota-derived metabolites, for the prevention or treatment of diseases. Claves is also exploring a gut microbiota modulation platform that can generate novel customized candidates capable of fine-tuning levels of gut metabolites, potentially treating a wide range of medical conditions.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited Partnership, SMTPH Limited and its subsidiaries. The Smart Pharma Group is wholly owned by Aptorum Group Limited. Smart Pharma Group focuses on systematically repurposing existing approved drugs for the treatment of a large array of orphan diseases. Smart Pharma Group conducts both computational based screening and preclinical validations in advancing the development of its repurposed candidates.
For more information about Smart Pharma Group, please visit www.smtph.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 Protein Cell. May; 9(5): 397–403.
2 Obes Surg. 2012 Jun;22(6):956-66
Tel: +852 2117 6611
Tel: + 852 2117 6611
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISACA Combines EuroCACS and CSX Conferences for the First Time in ISACA’s 50th Anniversary Year17.9.2019 14:15:00 CEST | Press release
Digital transformation and emerging technologies are the focus of ISACA’s combined EuroCACS/Cybersecurity Nexus (CSX) conference in Geneva, Switzerland, from 16-18 October 2019, as ISACA continues celebrating its 50th anniversary year. Sessions focused on DevOps, Agile, cryptocurrency, mobile payments, the Internet of Things (IoT), and other hot topics will bring together business technology professionals who lead information systems audit, risk, governance and security functions at their enterprises. Keynote speaker Anders Sorman-Nillson, a global futurist and innovation strategist, will open EuroCACS/CSX, and entrepreneur Jon Duschinsky, who was voted the second-most influential communicator in social innovation, will deliver the closing keynote. Also planned is a general-session panel to mark ISACA’s 50th anniversary in 2019 that features industry experts in innovation and a concurrent general session on “The Weaponisation of the IoT.” Attendees can advance their skills across techn
Andersen Global Expands in Rwanda17.9.2019 13:30:00 CEST | Press release
Andersen Global announced today a collaboration agreement with MRB Attorneys in Rwanda. The addition of the Kigali-based firm marks the 16th country with a presence in Africa for Andersen Global. MRB Attorneys was founded in 2013 by the firm’s five partners, who all have extensive experience in private and public legal consultancy services. Today, MRB’s eleven attorneys advise clients in corporate and commercial law, dispute resolution, energy and infrastructure, and government business and policy, with a heavy emphasis on banking and investment issues. They represent a broad clientele of banks, private and public companies, international organizations, and government agencies. “Andersen Global’s reputation of stewardship and transparency lines up well with what our clients value and have come to expect from us. The synergetic collaboration will be beneficial for our clients and our people,” said Emmanuel Butare, MRB Attorneys’ Managing Partner. “We are excited to work with like-minded
Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment17.9.2019 13:15:00 CEST | Press release
There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers. Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level. Proton therapy key players race for Asia markets Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers inc
CE China 2019: The International Brand Show for Consumer and Home Electronics17.9.2019 13:13:00 CEST | Press release
For the first time, CE China - a global IFA event - is held from 19 to 21 September 2019 in Guangzhou, the heart of China's trade and manufacturing business. The new date in September is perfect for preparation of Singles Day and end of year business in Asia. CE China provides an ideal platform and comprehensive services for consumer electronics and home appliance brands. The show has successfully established partnerships with leading global retailer chains such as Suning and Alibaba’s Tmall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005728/en/ Autonomous driving and new mobility at CE China 2019 CE China 2019 includes Connected Driving and New Energy Vehicles section in its spectrum tackling the trend of autonomous driving. Today, intelligent interconnection is not only a major trend in household appliances and electronic consumer goods, but also key to the automotive industry – bringing consumer electronics, hou
Zscaler Extends Edge Compute, Now Operating in Over 150 Data Centers17.9.2019 13:00:00 CEST | Press release
Zscaler, Inc., the leader in cloud security, today announced the Zscaler™ platform is now distributed across over 150 data centers, with the company’s latest data center opening in Val-du-Roi, Normandy, France. The expansion is part of the company’s ongoing mission to provide enterprise users with fast, secure, reliable access to applications and services regardless of location, empowering enterprises to accelerate their cloud adoption, securely. Built on the Zscaler multi-tenant cloud architecture, the Zscaler platform unifies secure internet gateway services, cloud sandbox, next-generation cloud firewall, data loss prevention, SSL decryption, bandwidth control, and more, with simplified policy management and reporting. It is now distributed across more than 150 data centers on six continents, which enables users to access the internet and cloud services securely from any device, any location, and over any network. “The physical footprint and end-to-end control of the network, infrast
Quake Global Launches Global LTE as the Latest Innovation for Our Best-Selling Products, QPRO™ and Q4000™17.9.2019 13:00:00 CEST | Press release
Quake Global, Inc. is excited to announce the availability of global LTE in our best-selling products, QPRO™ and Q4000™, which both come with bi-directional and dual-mode communication protocols over global satellite and cellular networks. Q4000 and QPRO are now available to our customers across the globe featuring the latest LTE communication technology, Cat M1/NB-IoT. This technology is designed to support M2M markets with a special focus on lower data costs for IoT data-driven applications. LTE is ideal for our customers who have equipment spanning significant geographic areas. The robust hardware housing and platform are designed to withstand extreme weather conditions, challenging work environments and are built to last. “At Quake, we continually strive to bring the most advanced telecommunication technology to our customers to ensure connectivity to assets in every part of the world,” said Polina Braunstein, CEO and President of Quake Global. Quake’s QRO and Q4000 family of produ